Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
Bruce Cree(University of California, San Francisco), Jeffrey L. Bennett(University of Colorado Denver), Eliezer Katz, William A. Rees(Mayo Clinic), Gary Cutter(Epilepsy Foundation), Brian G. Weinshenker(Mayo Clinic in Arizona), Orhan Aktaş(Heinrich Heine University Düsseldorf), Friedemann Paul(Max Delbrück Center), Hans‐Peter Hartung(The University of Sydney), Kazuo Fujihara(Tohoku University), Sean J. Pittock(Mayo Clinic), Romain Marignier(Hospices Civils de Lyon), Ho Jin Kim(National Cancer Center), Michael Smith(Amgen (United States)), Dewei She, Dean M. Wingerchuk(WinnMed), Daniel Cimbora, Ari Green(University of California, San Francisco)
Cited by 54
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k